Pacific Shuanglin Bio-pharmacy Co., Ltd.

000403.SZ - Shenzhen - Healthcare - Biotechnology

Pacific Shuanglin Bio-pharmacy Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of blood products in China and internationally. The company offers human serum albumin, human immunoglobulin (PH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin, rabies immunoglobulin, human coagulation factor VIII, human fibrinogen, lyophilized intravenous immunoglobulin (pH4), hepatitis B immunoglobulin (pH4), and human prothrombin complex concentrate, as well as intravenous cytomegalovirus immunoglobulin and intravenous respiratory syncytial virus immunoglobulin. It is also involved in blood acquisition; plasma collection; consulting; trading; investment activities; and technology promotion and application services. The company was formerly known as Southern Shuanglin Bio-pharmacy Co., Ltd. and changed its name to Pacific Shuanglin Bio-pharmacy Co., Ltd. in April 2021. Pacific Shuanglin Bio-pharmacy Co., Ltd. was founded in 1993 and is headquartered in Taiyuan, China.

Pacific Shuanglin Bio-pharmacy Co., Ltd. trades as 000403.SZ on Shenzhen in the Healthcare sector and Biotechnology industry. Its latest stored price is $11.88 as of June 12, 2026.

Data updated June 12, 2026

Financial Snapshot